Validation of iFR technology continues to grow

Philips is a leading innovator in image-guided therapies for cardiovascular diseases, as well as other diseases. The company has invested significantly in this important area in healthcare, as it offers strong benefits for both patients and health systems.

Last week, the European Society of Cardiology announced that it had incorporated iFR into its updated revascularization guidelines. This is a very important step in the validation of instant wave-free ratio (iFR) technology.

Unique to Philips, iFR is an innovative pressure-derived index a technology that’s used to assess coronary blockages in patients with ischemic heart disease (IHD), helping to identify the appropriate therapy for each patient. The technology offers a procedure that provides functional measurement while reducing patient discomfort by 90 percent, reducing costs by approximately 10 percent per patient over a one-year average and reducing time spent in the lab by 10 percent.

Diagnostic and Interventional Cardiology recently published an interesting feature giving an overview of the latest developments in this field, including the validation of iFR. You can read the full article here.